---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-142904"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2026-04-06T23:59:59+00:00"
generated_at: "2026-05-15T07:29:35.058526+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Neurocrine to acquire Soleno Therapeutics for $53.00 per share in cash

## Summary
- Tender offer for all Soleno shares at $53.00 cash each; no financing condition.
- Offer requires >50% shares tendered, HSR clearance, no material adverse effect.
- Termination fees: Soleno pays $95.25M for superior proposal; Neurocrine pays $141.5M for antitrust failure.
- Soleno board recommends tender; CEO and former CFO (1.01% combined) signed support agreements.
- Deal structured as tender offer followed by merger under Section 251(h) of DGCL.

## SEC filing metadata
- accession: 0001193125-26-142904
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2026-04-06T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000119312526142904/0001193125-26-142904-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000119312526142904/d110123d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-142904
- JSON: https://secwatch.observer/filing/0001193125-26-142904.json
- Plain text: https://secwatch.observer/filing/0001193125-26-142904.txt

## Key facts
- Material Agreements
  NEUROCRINE BIOSCIENCES INC entered into Merger Agreement with Soleno Therapeutics, Inc. (effective 2026-04-05).
  - Action: entry
  - Agreement: merger
  - Counterparty: Soleno Therapeutics, Inc.
  - Effective: 2026-04-05
  source text: On April 5, 2026, Neurocrine Biosciences, Inc., a Delaware corporation (“ Neurocrine ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among Neurocrine, Sigma Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Neurocrine (“ Purchaser ”), and Soleno Therapeutics, Inc., a Delaware corporation (“ Soleno ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/914475/000119312526142904/0001193125-26-142904-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.